Citations

Mayo Clinic

Showing 10 of 108523 citations.

The Effect of Repetition Rate on Air-Conducted Ocular Vestibular Evoked Myogenic Potentials (oVEMPs)
Bogle, Jamie M. , Zapala, David A., Burkhardt, Brittany, Walker, Kurt, Lundy, Larry, Shelfer, Janet, Pratt, Terri L., Garry, Millicent, Walker, David

American Journal of Audiology | May 21, 2015 | Volume: 24 | Issue: 3 | Pages: 411-418

10.1044/2015_aja-15-0011 | PMID 25997090 Get It

Purpose Ocular vestibular evoked myogenic potentials (oVEMPs) are used to describe utricular/superior vestibular nerve function; however, optimal recording parameters have not been fully established. This study investigated the effect of repetition rate on air-conducted oVEMPs. Method Ten healthy adults were evaluated using 500-Hz tone bursts (4-ms duration, Blackman gating, 122 dB pSPL). Four repetition rates were used (1.6, 4.8, 8.3, and 26.6 Hz) and resulting oVEMP response presence, amplitude, amplitude asymmetry, and n1/p1 latency were assessed. Results Response presence was significantly reduced for 26.6 Hz using monaural stimulation and for 8.3 Hz and 26.6 Hz for binaural stimulation. For monaural stimulation using 1.6, 4.8, and 8.3 Hz, no significant differences were noted for amplitude or latency. Responses obtained using binaural stimulation demonstrated a significant effect of rate on amplitude, with 8.3 Hz producing significantly reduced amplitude. Binaural amplitudes were significantly larger than monaural contralateral responses but with reduced response presence. No significant differences were noted for latency or amplitude asymmetry. Conclusion Using repetition rates of approximately 5 Hz or less may produce more consistent oVEMP response presence with minimal effects on amplitude for monaural or binaural recordings.
Texture analysis of images using a two-dimensional fast time-frequency transform
Cheng, Chun Hing , Pradhan, Pyari Mohan , Mitchell, J. Ross , Mitchell, Joseph Ross, Mitchell, Joseph Ross

Journal of Medical Imaging | May 21, 2015 | Volume: 2 | Issue: 2 | Pages: 024504

10.1117/1.jmi.2.2.024504 | PMID 26158108 Get It

Pancreatic oncogenic signaling cascades converge at Protein Kinase D1
Leitges, Michael , Störz, Peter , Liou, Geou‐Yarh , Leitges, Michael

Cell Cycle | May 21, 2015 | Volume: 14 | Issue: 10 | Pages: 1489-1490

10.1080/15384101.2015.1032646 | PMID 25928263 Get It

Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?
Stewart, Michael

Journal of Clinical Medicine | May 21, 2015 | Volume: 4 | Issue: 5 | Pages: 1079-1101

10.3390/jcm4051079 | PMID 26239466 Get It

The widespread use of drugs that bind diffusible vascular endothelial growth factor (VEGF) has revolutionized the treatment of neovascular age-related macular degeneration (AMD). The pivotal ranibizumab and aflibercept registration trials featured monthly intravitreal injections for 12 months, during which visual acuities and macular edema rapidly improved for the first 3 months and modest gains or stabilization continued until the primary endpoint. In many subsequent trials, patients were evaluated monthly and treated as-needed (PRN) according to the results of visual acuity (VA) testing, fundus examinations and optical coherence tomography scans. Compared to monthly-treated control groups, PRN treated patients require fewer injections during the first year but they also experience smaller VA gains (1–3 letters). A small number of prospective trials that directly compared monthly with PRN therapy showed that VA gains with discontinuous therapy lag slightly behind those achieved with monthly injections. Physicians recognize that monthly office visits with frequent intraocular injections challenge patients’ compliance, accrue high drug and professional service costs, and clog office schedules with frequently returning patients. To decrease the numbers of both office visits and anti-VEGF injections without sacrificing VA gains, physicians have embraced the treat-and-extend strategy. Treat-and-extend has not been studied as rigorously as PRN but it has become popular among both vitreoretinal specialists and patients. Despite the possible risks associated with discontinuous therapy (decreased VA and increased macular fluid), most physicians individualize treatment (PRN or treat-and-extend) for the majority of their patients. This review chapter explores the many advantages of individualized therapy, while balancing these against suboptimal responses due to the decreased frequency of anti-VEGF injections.
Frequency of Migraine Headaches in Patients With Fibromyalgia
Vij, Brinder, Whipple, Mary O. , Tepper, Stewart J. , Mohabbat, Arya B. , Stillman, Mark J., Vincent, Ann , Whipple, Mary

Headache: The Journal of Head and Face Pain | May 21, 2015 | Volume: 55 | Issue: 6 | Pages: 860-865

10.1111/head.12590 | PMID 25994041 Get It

Objective The purpose of this study was to evaluate the frequency of migraine headache in a large cohort of patients with fibromyalgia using a brief migraine headache‐screening tool. Background Several studies report a high prevalence of fibromyalgia among patients with migraine headaches, but there is a dearth of research evaluating the frequency of migraine headaches in patients with fibromyalgia, despite clinical observations suggesting that migraine headaches are common in patients with fibromyalgia. Design and Methods This was a cross‐sectional survey study. Patients (N = 3717) with a previous diagnosis of fibromyalgia who were members of the M ayo C linic F ibromyalgia R egistry were contacted by electronic survey and asked to complete a brief demographic and medical history questionnaire and the validated ID ‐ M igraine screener. Results A total of 1730 patients (46.5%) completed the electronic survey. The majority of participants were white (97.2%), female (92.5%), with a mean age of 56.2 (±13.1) years. Of the respondents, 966 (55.8%) met criteria for migraine headaches. Hypertension (309 [32.3%] vs 294 [40.1%], P = .004), asthma (312 [32.5%] vs 189 [25.9%], P = .011), irritable bowel syndrome (520 [54.6%] vs 348 [47.6], P = .017), chronic fatigue syndrome (486 [50.7%] vs 271 [37.1], P < .0001), depression (634 [66.5%] vs 413 [56.7%], P = .0002), anxiety (415 [43.5%] vs 252 [34.7%], P = .0011), and post‐traumatic stress disorder (172 [18.0%] vs 96 [13.2%], P = .006) were all significantly more common in those who met criteria for migraine headaches than those who did not. Conclusion The results of this study suggest that migraine headaches are common in patients with fibromyalgia. Clinicians who care for either population must be aware that these conditions commonly overlap and can significantly increase a patient's cumulative disease burden.
Social support and its implications in older, early‐stage breast cancer patients in CALGB 49907 (Alliance A171301)
Jatoi, Aminah , Muss, Hyman B. , Allred, Jake, Cohen, Harvey Jay, Ballman, Karla V. , Hopkins, Judith O. , Lafky, Jacqueline M., Wolff, Antonio C. , Kottschade, Lisa A. , Hurria, Arti , Allred, Jake B, Ballman, Karla, Lafky, Jacqueline, Kottschade, Lisa, Gajra, Ajeet , Gralow, Julie R. , Wolff, Antonio C , Ballman, Karla

Psycho-Oncology | May 21, 2015 | Volume: 25 | Issue: 4 | Pages: 441-446

10.1002/pon.3850 | PMID 25994447 Get It

AbstractBackgroundStudies point to a direct association between social support and better cancer outcomes. This study examined whether baseline social support is associated with better survival and fewer chemotherapy‐related adverse events in older, early‐stage breast cancer patients.MethodsThis study is a pre‐planned secondary analysis of CALGB 49907/Alliance A171301, a randomized trial that compared standard adjuvant chemotherapy versus capecitabine in breast cancer patients 65 years of age or older. A subset reported on the extent of their social support with questionnaires that were completed 6 times over 2 years.ResultsThe median age of this 331‐patient cohort was 72 years (range: 65, 90); 179 (55%) were married, and 210 (65%) lived with someone. One hundred forty‐five patients (46%) described a social network of 0–10 people; 110 (35%) of 11–25; and 58 (19%) of 26 or more. The Medical Outcomes Study (MOS) social support survey revealed that the median scores (range) for emotional/informational, tangible, positive social interaction, and affectionate social support were 94 (3, 100), 94 (0, 100), 96 (0, 100), and 100 (8, 100), respectively. Social support scores appeared stable over 2 years and higher (more support) than in other cancer settings. No statistically significant associations were observed between social support and survival and adverse events in multivariate analyses. However, married patients had smaller tumors, and those with arthritis reported less social support.ConclusionAlthough social support did not predict survival and adverse events, the exploratory but plausible inverse associations with larger tumors and arthritis suggest that social support merits further study. Copyright © 2015 John Wiley & Sons, Ltd.
Molecular markers for colorectal cancer screening
Dickinson, Brandon, Ahlquist, David A. , Kisiel, John, Kisiel, John B. , Grady, William M.

Gut | May 20, 2015 | Volume: 64 | Issue: 9 | Pages: 1485-1494

10.1136/gutjnl-2014-308075 | PMID 25994221 Get It

Colorectal cancer (CRC), although a significant cause of morbidity and mortality worldwide, has seen a declining incidence and mortality in countries with programmatic screening. Faecal occult blood testing and endoscopic approaches are the predominant screening methods currently. The discovery of the adenoma–carcinoma sequence and a greater understanding of the genetic and epigenetic changes that drive the formation of CRC have contributed to innovative research to identify molecular markers for highly accurate, non-invasive screening tests for CRC. DNA, proteins, messenger RNA and micro-RNA have all been evaluated. The observation of tumour cell exfoliation into the mucocellular layer of the colonic epithelium and proven stability of DNA in a harsh stool environment make stool DNA a particularly promising marker. The development of a clinically useful stool DNA test has required numerous technical advances, including optimisation in DNA stabilisation, the development of assays with high analytical sensitivity, and the identification of specific and broadly informative molecular markers. A multitarget stool DNA test, which combines mutant and methylated DNA markers and a faecal immunochemical test, recently performed favourably in a large cross-sectional validation study and has been approved by the US Food and Drug Administration for the screening of asymptomatic, average-risk individuals. The ultimate way in which molecular marker screening assays will be used in clinical practice will require additional studies to determine optimal screening intervals, factors affecting compliance, management of false-positive results, and the use of these assays in high-risk populations, as well as other considerations.
The bitter price of sweetness
Lanza, Ian R. , Lanza, Ian R

Science Translational Medicine | May 20, 2015 | Volume: 7 | Issue: 288 | Pages: No page available

10.1126/scitranslmed.aac4993 Get It

A study in human subjects links the obesogenic effects of fructose with hunger and appetite regulation in the brain.
The impact of the new proposed Papanicolaou Society of Cytopathology terminology for pancreaticobiliary cytology in endoscopic US‐FNA: A single‐Institutional experience
Munson, Valerie, Colletti, Shanna, Nassar, Aziza , Saieg, Mauro , Nassar, Aziza

Cancer Cytopathology | May 20, 2015 | Volume: 123 | Issue: 8 | Pages: 488-494

10.1002/cncy.21559 | PMID 25994860 Get It

BACKGROUNDThe Papanicolaou Society of Cytopathology has recently published a new proposal for pancreaticobiliary cytology terminology. For the current study, the authors applied this new classification for pancreaticobiliary cytology to a set of previously diagnosed endoscopic ultrasound (EUS)‐guided fine‐needle aspiration (EUS‐FNA) samples and correlated the results with those from the corresponding available final surgical specimens.METHODSPancreatic FNA specimens were retrospectively collected from a 12‐month period at the Mayo Clinic in Jacksonville, Florida. Cases with cytohistologic disagreement were reviewed to assess the reasons for discrepancies. The sensitivity and specificity of EUS‐FNA specimens were assessed using the Pearson chi‐square test.RESULTSOne hundred fifty‐five pancreatic FNA specimens were retrieved. The median patient age was 70 years (range, 25‐93 years). Eleven specimens previously classified as negative and 3 previously classified as non‐diagnostic were reclassified as neoplastic:other, as well as all specimens primarily classified as atypical or positive for neoplasm and half the specimens primarily classified as suspicious. All positive specimens remained within their same categories in the revised classification. Sixteen patients (10.3%) had surgical resection specimens available, and complete or partial agreement with FNA results was achieved in 13 of those surgical specimens (81.2%). Reasons for discrepancy comprised sampling errors in 5 specimens and an interpretation error in 1 specimen. Overall, sensitivity was 66.7%, specificity was 66.7%, the positive predictive value was 88.9%, and the negative predictive value was 33.3%.CONCLUSIONSThe application of the new proposed terminology for pancreaticobiliary cytology had a greater impact among specimens that were previously classified as atypical and suspicious. EUS‐FNA of the pancreas is a highly accurate method, and its use, allied with the new proposed terminology, may ultimately contribute to better outcomes. Cancer (Cancer Cytopathol) 2015;123:488–94. © 2015 American Cancer Society.
Hepatic insulin sensitivity in healthy and prediabetic subjects: from a dual- to a single-tracer oral minimal model
Visentin, R. , Man, Chiara Dalla , Basu, Rita , Basu, Ananda , Rizza, Robert A., Cobelli, Claudio , Dalla Man, Chiara

American Journal of Physiology-Endocrinology and Metabolism | May 19, 2015 | Volume: 309 | Issue: 2 | Pages: E161-E167

10.1152/ajpendo.00358.2014 | PMID 25991649 Get It

Recently, a model was proposed to assess hepatic insulin sensitivity during a meal, i.e., the ability of insulin to suppress glucose production (EGP), SIP. The model was developed on EGP data obtained from a triple-tracer meal and the tracer-to-tracee clamp technique and validated against the euglycemic hyperinsulinemic clamp. The aim of this study was to assess whether SIP can be obtained from plasma concentrations measured after a single-tracer meal by incorporating the above EGP model into the oral glucose minimal model by describing both glucose production and disposal (OMMPD). Triple-tracer meal data of two databases (20 healthy and 60 healthy and prediabetic subjects) were used. Virtually model-independent EGP estimates were calculated. OMMPD was identified on exogenous and endogenous glucose concentrations, providing indices of SIP, disposal insulin sensitivity (SID), and EGP. The model fitted the data well, and SIP and SID were estimated with precision in both databases (SIP = 5.48 ± 0.54 10−4 dl·kg−1·min−1 per μU/ml and SID = 9.93 ± 2.18 10−4 dl·kg−1·min−1 per μU/ml in healthy; SIP = 5.41 ± 3.55 10−4 dl·kg−1·min−1 per μU/ml and SID = 5.34 ± 6.17 10−4 dl·kg−1·min−1 per μU/ml, in healthy and prediabetic subjects). Estimated SIP and that derived from the triple-tracer EGP model were very similar on average. Moreover, the time course of EGP normalized to basal EGP (EGPb), and EGP/EGPb agreed with the results obtained using the triple-tracer method. In this study, we have demonstrated that SIP, SID, and EGP/EGPb time course can be estimated reliably from a single-tracer meal protocol in both healthy and prediabetic subjects.